Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022
August 04, 2022 at 04:01 pm EDT
Share
Cutera, Inc. reiterated revenue guidance for 2022. For the year, the company expects revenue to be in range of $255 million to $260 million, entirely absorbing the impact of the unprecedented foreign exchange headwinds of $15 million, implying constant currency growth of 17% to 19%. This guidance does not include revenue from the AviClear device as it continue with its limited commercial release.
The company plans to add over 100 new AviClear devices into the market during the course of the third quarter of 2022. Based on current AviClear trends, management expects to move into a full commercial launch by the end of the current calendar year.
Cutera, Inc. develops, manufactures, distributes, and markets energy-based product platforms for medical practitioners, enabling them to offer treatments to their customers. The Company distributes third-party manufactured skincare products and secret systems and consumables. Its system platforms include AviClear, enlighten, excel, truSculpt, Secret PRO, Secret RF, and xeo. The Companyâs Cutera Core segment consists of the Companyâs systems, consumables, skincare, and service businesses. The Cutera Core segment develops, distributes and manufactures energy-based systems for medical practitioners in addition to distributing third-party manufactured skincare products in Japan. The Companyâs AviClear segment consists of the AviClear business. The Companyâs acne solution, AviClear, is a prescription-free, drug-free laser treatment for the treatment of mild to severe acne. Its products include CUTERA, ACUTIP 500, AVITM, AVI360, AVIANALYTICSTM, AVICARE COOLGLIDE, and more.
CUTERA, INC. 
